nevirapine has been researched along with foscarnet in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Dornadula, G; Grobler, JA; Hazuda, DJ; Miller, MD; Rice, MR; Simcoe, AL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deibel, MR; Dueweke, TJ; Kézdy, FJ; Tarpley, WG; Waszak, GA | 1 |
| Cheng, YC; Dutschman, GE; Im, GJ; Mellors, JW; Tramontano, E; Winkler, SR | 1 |
| Cheng, YC; Tramontano, E | 1 |
| Bäckbro, K; Noréen, R; Oberg, B; Unge, T; Vrang, L; Zhang, H | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Bazmi, HZ; La Colla, P; Mellors, JW; Piras, G; Putzolu, M; Tramontano, E | 1 |
| Auwerx, J; Balzarini, J; De Clercq, E; Klarmann, GJ; North, TW; Preston, BD | 1 |
| Auwerx, J; Balzarini, J; De Clercq, E; Esnouf, R | 1 |
1 review(s) available for nevirapine and foscarnet
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for nevirapine and foscarnet
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzoxazoles; Cyclopropanes; DNA; Dose-Response Relationship, Drug; Drug Resistance, Viral; Enzyme Inhibitors; HIV Reverse Transcriptase; In Vitro Techniques; Inhibitory Concentration 50; Ligands; Models, Genetic; Oxazines; Pyridones; Reverse Transcriptase Inhibitors; Stochastic Processes; Transcription, Genetic; Virus Replication | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Benzodiazepines; Binding, Competitive; Dideoxynucleosides; Foscarnet; HIV-1; Imidazoles; Indoles; Nevirapine; Phosphonoacetic Acid; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 1992 |
In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
Topics: Antiviral Agents; Base Sequence; Benzodiazepines; CD4-Positive T-Lymphocytes; Cloning, Molecular; Drug Resistance, Microbial; Foscarnet; Gene Expression; HeLa Cells; HIV-1; Humans; Imidazoles; Molecular Sequence Data; Nevirapine; Phosphonoacetic Acid; Polymerase Chain Reaction; Pyridines; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 1992 |
HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.
Topics: Antiviral Agents; Foscarnet; HIV-1; Kinetics; Nevirapine; Phosphonoacetic Acid; Pyridines; Reverse Transcriptase Inhibitors; Templates, Genetic; Zidovudine | 1992 |
Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
Topics: Amino Acids; Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Binding, Competitive; Deoxyguanine Nucleotides; Dideoxynucleotides; Foscarnet; HIV Reverse Transcriptase; Humans; Imidazoles; Kinetics; Molecular Sequence Data; Mutation; Nevirapine; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sensitivity and Specificity | 1994 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.
Topics: Amino Acids; Diphosphates; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Stability; Foscarnet; HIV Reverse Transcriptase; Kinetics; Mutagenesis, Site-Directed; Nevirapine; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Topics: Amino Acid Sequence; Deoxyguanine Nucleotides; Dideoxynucleotides; Drug Resistance, Microbial; Escherichia coli; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Immunodeficiency Virus, Feline; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Nevirapine; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid | 2002 |
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Catalysis; Cats; Deoxyguanine Nucleotides; Dideoxynucleotides; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Immunodeficiency Virus, Feline; Kinetics; Molecular Sequence Data; Nevirapine; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Species Specificity; Sulfur Compounds | 2004 |